Pelthos Therapeutics Inc. PTHS
- Market cap
- $85.8M
- P/E
- 0.0×
Follow PTHS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 4.50 | 6.30 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 60.00 | 54.29 |
High Price
|
|||
| — | — | — | — | — | — | — | 4 | 11 | 92 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | 17 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | — | 76.25% |
Gross Margin
|
|||
| — | — | — | — | — | (1) | (2) | (7) | (8) | (51) |
EBT
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (301.91%) |
EBT Margin
|
|||
| — | — | — | — | — | (1) | (2) | (7) | (8) | (43) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 1 | 3 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 8.93 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (56.52) | (57.80) | (14.30) | (23.04) |
Earnings/Sh
|
|||
| — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.01) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.05) |
Capex/Sh
|
|||
| — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.07) |
Free CF/Sh
|
|||
| — | — | — | — | — | 0.00 | (85.21) | (50.47) | (4.87) | 20.68 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 0 | 0 | 1 | 2 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 1.50 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | — | (3.28) |
EV/FCF
|
|||
| — | — | — | — | — | (2) | (2) | (1) | (6) | (23) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Capex
|
|||
| — | — | — | — | — | (2) | (2) | (1) | (6) | (23) |
FCF
|
|||
| — | — | — | — | — | (3) | (4) | (6) | (3) | 27 |
Working Cap'
|
|||
| — | — | — | — | — | — | 1 | 1 | 2 | 31 |
Total Debt
|
|||
| — | — | — | — | — | — | 0 | 1 | 2 | 13 |
Net Debt
|
|||
| — | — | — | — | — | (4) | (4) | (6) | (3) | 39 |
Sh' Equity
|
|||
| — | — | — | — | — | 0.00% | (8,924.14%) | (9,743.63%) | (1,085.71%) | (65.75%) |
ROA
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (38.76%) |
ROIC
|
|||
| — | — | — | — | — | 0.00% | 66.57% | 145.42% | 173.72% | (239.55%) |
ROE
|
|||
Pelthos Therapeutics Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ATRA Atara Biotherapeutics, Inc. | $85.7M | 0.0× | Compare |
| RLYB Rallybio Corporation | $88.2M | 2.1× | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $83.2M | 0.0× | Compare |
| ICCC ImmuCell Corporation | $90.6M | 117× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CGTX Cognition Therapeutics, Inc. | $90.7M | 0.0× | Compare |
| ACRV Acrivon Therapeutics, Inc. | $90.9M | 0.0× | Compare |
| GANX Gain Therapeutics, Inc. | $80.3M | 0.0× | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | Compare |
Pelthos Therapeutics Inc. (PTHS) key facts
- Pelthos Therapeutics Inc. (PTHS) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- Pelthos Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.8 million.
- As of September 25, 2026, PTHS traded at $22.19, a market capitalization of $85.8 million.
- Return on equity was −239.6% and debt-to-equity -46.58.
Pelthos Therapeutics Inc. (PTHS) Latest News
20 Aug
Pelthos Therapeutics Inc. (PTHS) released its Q2 2026 earnings call transcript covering financial results and outlook. Q2 2026 earnings disclosure provides critical data on financial health and operations.
14 Aug
Pelthos Therapeutics Inc. (PTHS) released Q2 earnings call highlights covering financial results, operational updates, and forward guidance. Quarterly earnings and guidance can shift near-term investor sentiment and valuation but rarely transform long-term company trajectory.
13 Aug
Pelthos Therapeutics Inc (PTHS) reported 45% revenue growth in Q2 2026 earnings call highlights. 45% revenue surge signals major positive shift in financial trajectory and investor outlook.
Pelthos Therapeutics Inc. released its Q2 2026 earnings call summary detailing financial results and business updates. Q2 2026 earnings call directly informs investors on Pelthos Therapeutics Inc. financials and outlook, likely moving stock price.
Pelthos Therapeutics Inc. announced its second quarter 2026 financial results. Quarterly financial results provide performance data that can moderately shift investor views and stock trajectory.
6 Aug
Pelthos Therapeutics Inc. shares rose due to its role as a biotech dealmaker with ties to Merck and Travere. Deal links to Merck and Travere indicate major strategic moves that can significantly shift Pelthos trajectory and investor sentiment.
15 May
Pelthos Therapeutics Inc. (PTHS) presented Q1 financial results, operational updates, and forward guidance during its earnings call. Q1 earnings metrics and guidance can shift near-term investor views on PTHS valuation and operations.
Pelthos Therapeutics Inc. held its Q1 2026 earnings call covering financial results, operational updates and forward outlook for the company. Quarterly earnings calls deliver performance data and guidance that can shift near-term sentiment without guaranteeing structural change.
14 May
Pelthos Therapeutics Inc. (PTHS) Q1 2026 earnings call highlights revenue surge and strategic advancements. Revenue surge combined with strategic initiatives signals significant positive shift in financial performance and growth trajectory for PTHS.
Pelthos Therapeutics Inc. (PTHS) announced first quarter 2026 financial results. Quarterly financial results for a therapeutics company typically reveal cash position, R&D expenses, and pipeline updates that significantly sway stock performance and investor outlook.
Pelthos Therapeutics Inc. (PTHS) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite loss moderately boosts financial sentiment without altering long-term trajectory.
31 Mar
Pelthos Therapeutics Inc. (PTHS) announced dosing the first patient in its Phase 1b/2a clinical trial of CT2000 for eye pain. First patient dosing in Phase 1b/2a trial signals clinical progress that may moderately boost market sentiment and pipeline credibility.
29 Mar
Pelthos Therapeutics outlines public-market entry strategy, reports ZELSUVMI sales surge, and announces addition of Xepi and Xeglyze products during Roth interview. Public listing plans, surging ZELSUVMI, and new product additions represent major strategic expansions boosting growth trajectory and investor interest.
19 Mar
Pelthos Therapeutics Inc. (PTHS) reported a prescription surge in Q4 2025 earnings call highlights, signaling strong demand growth. Prescription surge reflects major revenue potential and improved market positioning for PTHS.
Pelthos Therapeutics Inc. (PTHS) released Q4 earnings call highlights covering financial results, pipeline updates, and strategic outlook. Q4 earnings highlights detail financial performance and pipeline progress, likely driving significant shifts in investor sentiment and stock trajectory.
Pelthos Therapeutics Inc. (PTHS) reported a Q4 loss but exceeded revenue estimates. Q4 revenue beat despite loss moderately bolsters financial performance and investor sentiment.
Pelthos Therapeutics Inc. (PTHS) announced fourth quarter and full-year 2025 financial results. Financial results announcements influence investor sentiment and assessments of operational health and runway.
15 Jan
Horizon Technology Finance has provided Pelthos Therapeutics Inc. with a venture loan facility of up to $50 million. This funding is intended to support the company's development of innovative therapies for patients with rare diseases. The loan facility will offer Pelthos the necessary capital to advance its clinical programs and operational initiatives. The $50 million venture loan facility is a significant financial boost that could enhance Pelthos Therapeutics' development capabilities and market positioning.
13 Jan
Pelthos Therapeutics Inc. has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance. This financing is intended to support the company's ongoing development and operational activities. The loan facility includes an initial draw of $25 million, with the potential for an additional $25 million based on certain conditions. The agreement is expected to enhance Pelthos's financial flexibility as it advances its therapeutic programs. The loan facility provides significant financial support that may positively influence Pelthos's operational capabilities and product development.
5 Jan
Pelthos Therapeutics Inc. has acquired Xeglyze® (abametapir), a topical treatment for head lice, expanding its product portfolio. This acquisition aims to enhance Pelthos's offerings in the dermatological space and address the growing demand for effective head lice treatments. The deal is expected to strengthen the company's market position and drive future growth. Acquiring Xeglyze® represents a significant strategic move that could enhance Pelthos's competitive positioning and market presence.
23 Dec
Pelthos Therapeutics Inc. has appointed Andrew Einhorn to its Board of Directors, expanding its leadership team. Einhorn brings extensive experience in the biotechnology sector, which is expected to enhance the company's strategic direction and governance. The appointment of a seasoned professional may positively influence the company's strategic decisions and governance.
4 Dec
Pelthos Therapeutics Inc. has signed a significant agreement with a major pharmacy benefit manager to enhance patient access to its product, ZELSUVMI™ (berdazimer) Topical Gel, 10.3%. This partnership aims to improve the availability of the treatment for patients, potentially increasing its market reach and adoption. The agreement is expected to significantly enhance patient access and market penetration for ZELSUVMI™, impacting Pelthos Therapeutics' future performance.
2 Dec
Pelthos Therapeutics Inc. (PTHS) will present at the Piper Sandler 37th Annual Healthcare Conference, showcasing its latest developments and strategic initiatives to potential investors and industry stakeholders. Participation in a prominent healthcare conference can enhance visibility and investor interest, potentially influencing market sentiment.
20 Nov
Ligand Pharmaceuticals has seen a 92% increase in stock value this year, driven by its role in the development of two major drugs. The company's strategic partnerships and innovative technologies have positioned it favorably in the pharmaceutical market, attracting investor interest and boosting its financial outlook. Analysts highlight the potential for continued growth as Ligand leverages its assets and expands its pipeline, making it a noteworthy player in the industry. Ligand's significant stock increase and strategic positioning may moderately influence market sentiment and competitive dynamics for Pelthos Therapeutics.
13 Nov
Pelthos Therapeutics Inc. (PTHS) reported its financial results for the third quarter of fiscal 2025, highlighting key metrics such as revenue, expenses, and net income. The company continues to focus on its pipeline development and strategic initiatives aimed at enhancing shareholder value. Management provided insights into future growth prospects and ongoing projects, emphasizing their commitment to innovation in therapeutics. Financial results indicate moderate performance, impacting future growth and investor sentiment.
10 Nov
Pelthos Therapeutics Inc. (PTHS) has received an upgraded growth outlook, leading to a positive adjustment in its target price. Analysts are optimistic about the company's future performance, citing improved market conditions and potential advancements in its product pipeline. This shift in sentiment reflects confidence in Pelthos's strategic direction and operational capabilities, which may enhance investor interest and market positioning. The improved growth outlook and target price adjustment indicate significant potential for Pelthos's future performance and market sentiment.
7 Nov
Pelthos Therapeutics Inc. has acquired Xepi® (ozenoxacin) Cream, 1%, a topical antibiotic used for treating skin infections. The acquisition is part of Pelthos's strategy to expand its product portfolio. Additionally, the company announced an $18 million private convertible notes financing to support its growth initiatives and operational needs. The acquisition of Xepi® and the financing are significant strategic moves that could enhance Pelthos's product offerings and financial position.
9 Oct
Pelthos Therapeutics Inc. has launched the 'Moms Against Molluscum' movement to support families affected by molluscum contagiosum, a common viral skin infection in children. The initiative aims to raise awareness, provide resources, and foster a community for those dealing with the condition. Pelthos is committed to addressing the challenges faced by families and enhancing understanding of the infection. The initiative may enhance brand visibility and community engagement, potentially influencing market sentiment and product interest.
18 Aug
Pelthos Therapeutics Inc. reported its financial results for the second quarter of 2025, focusing on legacy operations. The company provided updates on its business strategy and performance metrics, highlighting key financial figures and operational developments. The financial results and business updates indicate a moderate influence on Pelthos Therapeutics' future performance and market positioning.
10 Jul
Pelthos Therapeutics has launched ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum. This innovative product offers a new option for patients seeking effective management of this common skin condition, marking a significant advancement in dermatological care. The launch of an FDA-approved treatment for a common condition is likely to significantly impact market positioning and investor sentiment for Channel Therapeutics.